NEW MJ NEWS

Cronos Group, Inc. to Host Earnings Call

Cronos Group, Inc. (NASDAQ:CRON) will be discussing their earnings results in their 2020 Third Quarter Earnings call to be held on November 5, 2020 at 8:30 AM Eastern Time.

To listen to the event live or access a replay of the call – visit
https://www.investornetwork.com/event/presentation/70536

To receive updates for this company you can register by emailing info@investornetwork.com or by clicking get investment info from the company’s profile.

– ADVERTISEMENT –

About Investor Network

Investor Network (IN) is a financial content community, serving millions of unique investors market information, earnings, commentary and news on what’s trending. Dedicated to both the professional and the average traders, IN offers timely, trusted and relevant financial information for virtually every investor. IN is an Issuer Direct brand, to learn more or for the latest financial news and market information, visit www.investornetwork.com. Follow us on Twitter @investornetwork.

SOURCE: Investor Network

View source version on accesswire.com:
https://www.accesswire.com/614632/Cronos-Group-Inc-to-Host-Earnings-Call


MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Plandaí Biotechnology, Inc. (PLPL) Discusses Cannabis Extract Opportunities and Research Potential

Plandai Biotechnology Discusses Cannabis Extract Opportunities and Research Potential Plandaí Biotechnology, Inc.…

Ascend Wellness Holdings, Inc. (AAWH) Participation in Upcoming Conferences in April

AWH Announces Participation in Upcoming Conferences in April Ascend Wellness Holdings, Inc.…

Aphria Inc.’s (APHA) to Report Q1 Earnings: What’s in the Offing?

Aphria (APHA) to Report Q1 Earnings: What’s in the Offing? Aphria Inc.’s…

Cara Therapeutics (CARA) & Enteris BioPharma, Inc. Doses First Patient in Phase 1 Trial of Oral KORSUVA™

Enteris BioPharma’s “Feasibility-to-Licensing” Partner, Cara Therapeutics, Doses First Patient in Phase 1…